Investigational drug · Phase 3
RP2
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Biliary Tract Cancer, Metastatic Uveal Melanoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Apr 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
14
Any phase or sponsor naming "RP2"
First trial start
2024
Aug 1, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "RP2", any sponsor or status.
- Phase 210
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Biliary Tract Cancer
- Metastatic Uveal Melanoma
Approved drugs for the same conditions: Melanoma · Liver cancer (hepatocellular carcinoma) · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "RP2" as an intervention, largest first.
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaPivotal-lookingRecruiting
Replimune, Inc.Industry
NCT06581406 · 280 participants (planned) · Start Dec 17, 2024 · Primary completion Jan 2030
Drug: RP2; Ipilimumab and 1 more · For: Metastatic Uveal Melanoma
Sites: Scottsdale, Arizona; La Jolla, California; Los Angeles, California · 33 sites in all
- P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple MyelomaActive, not recruiting
Poseida Therapeutics, Inc.Industry
NCT04960579 · 275 participants (planned) · Start May 5, 2022 · Primary completion Mar 2029
Drug: P-BCMA-ALLO1 CAR-T cells; Rimiducid and 1 more · For: Multiple Myeloma
Sites: Goodyear, Arizona; San Diego, California; San Francisco, California · 23 sites in all
Hoffmann-La RocheRoche (Genentech) (RHHBY)
NCT01871805 · 134 participants · Start Sep 30, 2013 · Primary completion Oct 24, 2014
Drug: Alectinib · For: Non-Small Cell Lung Cancer
Sites: Birmingham, Alabama; Irvine, California; La Jolla, California · 42 sites in all
pharmaand GmbHIndustry
NCT01009190 · 85 participants · Start Feb 2010 · Primary completion Apr 2014
Drug: PF-01367338; Carboplatin and 2 more · For: Advanced Solid Tumors
Sites: Oxford, United Kingdom; Sutton, United Kingdom; Belfast, United Kingdom · 6 sites in all
Replimune, Inc.Industry
NCT05733598 · 60 participants (planned) · Start Aug 1, 2024 · Primary completion Dec 1, 2027
Drug: RP2; Bevacizumab and 3 more · For: Hepatocellular Carcinoma; Biliary Tract Cancer
Sites: Beverly Hills, California; La Jolla, California; Miami, Florida · 12 sites in all
- Study of RP2 Monotherapy and RP2 in Combination With Nivolumab in Patients With Solid TumorsActive, not recruiting
Replimune, Inc.Industry
NCT04336241 · 36 participants (planned) · Start Oct 17, 2019 · Primary completion Oct 31, 2026
Drug: RP2; nivolumab · For: Cancer
Sites: Barcelona, Spain; Madrid, Spain; Valencia, Spain · 6 sites in all
Abramson Cancer Center at Penn MedicineAcademic, hospital or other
NCT07059611 · 34 participants (planned) · Start Apr 1, 2027 · Primary completion Nov 1, 2027
Drug: RP2; Pegfilgrastim and 1 more · For: Gastric Adenocarcinoma; Esophageal Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma
Sites: Philadelphia, Pennsylvania
- Neoadjuvant RP2 + Nivolumab in Patients With MelanomaNot yet recruiting
Yana NajjarAcademic, hospital or other
NCT07862530 · 34 participants (planned) · Start Dec 31, 2026 · Primary completion Feb 27, 2028
Drug: RP2 (vusolimogene oderparepvec); Nivolumab · For: MelanomaCutaneous Melanoma Resectable, Melanoma
Sites: Pittsburgh, Pennsylvania
Eisai Inc.Eisai
NCT01433991 · 30 participants · Start Oct 13, 2011 · Primary completion Mar 18, 2015
Drug: Golvatinib; Lenvatinib and 1 more · For: Advanced Solid Tumors
Sites: Boston, Massachusetts · 2 sites in all
Glenn J. HannaAcademic, hospital or other
NCT06623110 · 25 participants (planned) · Start Jan 1, 2025 · Primary completion Jan 1, 2027
Drug: RP2 Injection · For: High-Risk Oral Precancerous Disease
Sites: Boston, Massachusetts · 2 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- SHAP-guided variable selection with radial basis function Kolmogorov-Arnold networks for interpretable infrared spectral quantification.
Chen X, Zhang J, Li J, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Rapid and nondestructive prediction of chlorophyll fluorescence parameter Fv/Fm in Juncao leaves based on Vis-NIR spectroscopy and deep transfer learning.
Xu J, Zheng C, Lin J, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Toward generalized peach firmness evaluation: An adaptive spectral-vibration fusion and cross-cultivar transfer learning strategy.
Jiang B, Wu Q, Fei S, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Potato LAI estimation by enhancing spectral features of reflectance and fluorescence to improve application potential among different varieties.
Liu M, Liu G, Guo C, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
- Early diagnosis of cadmium stress in rice by intelligent profiling of multiple response indicators with portable Raman SERS and deep learning.
Wu T, Zhang L, Ding Y, et al. · Talanta 2027
- Deep learning-enabled multi-modal fusion of smartphone vision and portable spectroscopy for apple non-destructive quality inspection.
Guo Q, Lin Z, Yan X, et al. · Spectrochim Acta A Mol Biomol Spectrosc 2027
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.